Methylation biomarkers, kits, and methods for assisting in the detection of EGFR gene mutations in lung cancer somatic cells
By detecting specific DNA methylation regions in lung cancer somatic cells and establishing a predictive model, the problem of detecting EGFR gene mutations in existing technologies has been solved, achieving detection with higher sensitivity and specificity, and is suitable for early screening and efficacy evaluation of lung cancer.
Patent Information
- Application Number
- CN202211699904.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2022-12-28
- Publication Date
- 2026-11-17
- Estimated Expiration
- 2042-12-28
AI Technical Summary
Existing technologies are not easy to use to detect EGFR gene mutations in lung cancer somatic cells, especially in the absence of normal tissue controls. Furthermore, traditional detection methods are invasive to patients and lack sufficient sensitivity and specificity.
Using methylation biomarkers, including specific DNA regions (such as chr19:13198677-13198878, chr6:25882281-25882482, etc.), combined with bisulfite conversion and high-throughput sequencing technologies, a predictive model was established to assist in the detection of EGFR gene mutations by detecting methylation differences.
It improves the sensitivity and specificity of detecting EGFR gene mutations in lung cancer somatic cells, simplifies the detection process, reduces invasiveness to patients, and is suitable for early screening, auxiliary diagnosis, efficacy evaluation, and recurrence monitoring of lung cancer.
Smart Images

Figure CN117660640B_ABST
Abstract
Description
Technical Field
[0001] This invention belongs to the field of biotechnology, and more specifically, this invention relates to a methylation biomarker, kit, and method for assisting in the detection of EGFR gene mutations in lung cancer somatic cells. Background Technology
[0002] From a pathological and therapeutic perspective, lung cancer can be broadly classified into two categories: non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). NSCLC accounts for approximately 80%–85% of cases, including histological subtypes such as adenocarcinoma and squamous cell carcinoma, while the remainder is small cell lung cancer [National Health Commission of the People's Republic of China, He Jie, Wu Yilong, Gao Shugeng, & Wang Jie. (2022). Guidelines for the Diagnosis and Treatment of Primary Lung Cancer (2022 Edition). Exploration of Rational Drug Use in China, 19(9), 28.]. Numerous reports have also confirmed a high correlation between mutations, fusions, and gene expansions of various cancer-related genes and the formation of lung cancer, particularly NSCLC.
[0003] Epidermal growth factor receptor (EGFR) is a membrane surface receptor with tyrosine kinase activity. Its three subregions are key to mediating signal transduction. By forming various homologous or heterologous dimers with other receptors, it can transmit different extracellular stimuli into the cell and activate multiple downstream signaling pathways, producing a variety of biological effects. It can regulate transcription factors and activate the transcription of related genes, triggering anti-apoptosis, cell proliferation, angiogenesis, and even tumor invasion and metastasis. Targeted therapy for lung cancer is currently widely used in non-small cell lung cancer (NSCLC) containing EGFR mutations. This is because EGFR is one of the common driver genes in NSCLC. Cancer cells containing EGFR mutations have a growth advantage over their wild-type counterparts and are also more sensitive to EGFR tyrosine kinase inhibitors [Eberhard DA, Johnson BE, Amler LC, et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol. 2005; 23(25):5900-5909. doi:10.1200 / JCO.2005.02.857]. In addition, the presence of EGFR mutations can serve as a prognostic factor. EGFR mutations are the most common in lung adenocarcinoma, and the mutation frequency varies among different ethnic groups, with Asians (20%-40%) being more common than Caucasians (5%-20%).EGFR mutations are most commonly associated with changes in exons 18-21, typically exon 19 deletions and exon point mutations [John T, Liu G, Tsao MS. Overview of molecular testing in non-small-cell cancer: mutational analysis, gene copy number, protein expression and other biomarkers of EGFR for the prediction of response to tyrosine kinase inhibitors. Oncogene. 2009; 28Suppl 1:S14-S23. doi:10.1038 / onc.2009.197].
[0004] Extensive published clinical data demonstrates the spatial and temporal heterogeneity of tumors, manifested in the diverse range of sensitive and resistant mutations corresponding to targeted drugs. For example, mutations can occur in different genes, at different sites within the same gene, or in different mutation types (point mutations, small fragment insertions / deletions, copy number variations, gene fusions). Tissue biopsy pathology, as the gold standard for establishing molecular subtyping of tumors, typically requires comparing the genomic sequences of tumor tissue with those of normal tissue from the same individual to pinpoint the location and type of mutations. However, obtaining normal tissue samples is often difficult, posing a significant challenge to tissue biopsy and its detection techniques. Furthermore, tissue biopsy requires surgical sampling or puncture, causing physical harm to patients and making it psychologically difficult for them to accept. Peripheral blood cell-free DNA (cfDNA) testing, as a non-invasive "liquid biopsy" technique, is simpler and easier to perform than tissue biopsy, and is more readily accepted by patients.
[0005] DNA methylation is an important epigenetic modification in the human genome, playing a crucial role in gene transcription and participating in transcriptional regulation in conjunction with histone modification and chromatin remodeling. In tumors, it manifests primarily as hypermethylation of tumor suppressor genes and DNA repair genes, hypomethylation of repetitive DNA sequences, and loss of imprinting in certain genes, thus demonstrating its close relationship with tumorigenesis. Analyzing high-throughput methylation sequencing data from tumor tissue samples with different mutations, and constructing a reasonable biostatistical model, can effectively predict specific mutations in unknown samples. This can significantly reduce experimental and analytical costs, improve detection sensitivity and specificity, and promote basic and clinical research. Currently, routine methods for detecting EGFR gene mutations include WGS, WES, genepanel, and RNA-seq, while methods for detecting methylation using cfDNA include polymerase chain reaction (PCR)-based techniques and methods related to next-generation sequencing technologies.
[0006] In summary, it is necessary to find a detection method that is not only simple and feasible, but also overcomes the low signal of individual DNA methylation, while improving the sensitivity and specificity of mutation detection. Summary of the Invention
[0007] Based on this, the purpose of the present invention is to provide a methylation biomarker, kit and method for assisting in the detection of EGFR gene mutations in lung cancer somatic cells.
[0008] The technical solutions for achieving the above-mentioned objectives include the following.
[0009] In a first aspect, the present invention provides a methylation biomarker for assisting in the detection of EGFR gene mutations in lung cancer somatic cells, wherein the methylation biomarker includes at least one of chr19:13198677-13198878, chr6:25882281-25882482, chr6:25882382-25882583, chr2:232545785-232545986, and chr10:94303998-94304199.
[0010] In a second aspect, the invention provides the use of reagents for detecting the above-mentioned methylation biomarkers in the preparation of kits for predicting, detecting, classifying, monitoring treatment, prognosticating, or otherwise evaluating EGFR gene mutations in somatic cells of lung cancer.
[0011] A third aspect of the present invention provides a lung cancer somatic cell EGFR gene mutation auxiliary detection kit, comprising reagents for detecting the degree of methylation difference of the above-mentioned methylation biomarkers.
[0012] In a fourth aspect, the present invention provides the application of the above-described kit in predicting, detecting, classifying, monitoring treatment, assessing prognosis, or otherwise evaluating EGFR gene mutations in somatic cells of lung cancer.
[0013] A fifth aspect of the present invention provides a method for assisting in the detection of EGFR gene mutations in lung cancer somatic cells. It includes the following steps: extracting peripheral blood DNA from a biological sample to be tested; converting the DNA to bisulfite; and detecting the degree of methylation difference of the aforementioned methylation biomarkers.
[0014] The inventors of this invention discovered 224 DNA methylation regions, including chr19:13198677-13198878. By detecting different combinations of these regions and establishing predictive models using methods such as random forests or logistic regression, they found that these models can assist in detecting whether harmful mutations have occurred in the EGFR gene in lung cancer somatic cell samples. They also overcome the problem of low signal intensity from individual DNA methylation regions and improve the sensitivity and specificity of detection, thus providing more effective auxiliary detection services for targeted drug therapy in clinical lung cancer patients. Furthermore, based on the detection of the methylation status of these DNA methylation biomarkers in sample somatic cells, a more comprehensive analysis of methylation changes during the occurrence and development of lung cancer can be performed. This can be applied to early lung cancer screening, auxiliary diagnosis, efficacy evaluation, and recurrence monitoring, providing more accurate and sensitive detection services for clinical practice. Attached Figure Description
[0015] Figure 1 This is a heatmap of 224 markers in 14 EGFR_mut and 6 EGFR_wt samples in the example.
[0016] Figure 2 The ROC plot of 224 markers in the example is shown in 14 EGFR_mut and 6 EGFR_wt samples. Detailed Implementation
[0017] To facilitate understanding of the present invention, a more complete description will be provided below. The present invention can be implemented in many different forms and is not limited to the embodiments described herein. Rather, these embodiments are provided to provide a thorough and complete understanding of the disclosure of the present invention.
[0018] Unless otherwise defined, all technical and scientific terms used in this invention have the same meaning as commonly understood by one of ordinary skill in the art to which this invention pertains. The terminology used in this specification is for the purpose of describing particular embodiments only and is not intended to limit the invention. The term "and / or" as used in this invention includes any and all combinations of one or more of the associated listed items.
[0019] Unless otherwise specified, experimental methods in the following examples were performed under standard conditions, such as those described in Green and Sambrook et al., *Molecular Cloning: A Laboratory Manual* (2013), or as recommended by the manufacturer. All commonly used chemical reagents used in the examples are commercially available products.
[0020] In some embodiments of the present invention, a methylation biomarker for assisting in the detection of EGFR gene mutations in lung cancer somatic cells is disclosed, wherein the methylation biomarker includes at least one of chr19:13198677-13198878, chr6:25882281-25882482, chr6:25882382-25882583, chr2:232545785-232545986, and chr10:94303998-94304199.
[0021] In some embodiments, the methylation biomarkers include at least one of chr19:13198677-13198878, chr6:25882281-25882482, chr6:25882382-25882583, chr2:232545785-232545986, and chr10:94303998-94304199.
[0022] In some embodiments, the methylated biomarkers include at least one of chr19:13198677-13198878, chr6:25882281-25882482, chr6:25882382-25882583, chr2:232545785-232545986, chr10:94303998-94304199, chr1:50881885-50882086, chr9:130700842-130701043, chr9:96068585-96068786, chr6:28303851-28304336, and chr17:59539353-59539707.
[0023] In some embodiments, the methylation biomarkers include chr19:13198677-13198878, chr6:25882281-25882482, chr6:25882382-25882583, chr2:232545785-232545986, chr10:94303998-94304199, chr1:50881885-50882086, chr9:130700842-130701043, chr9:96068585-96068786, chr6:28303851-28304336, and chr17:59539353-5953. Any at least one of 9707, chr9:135037068-135037269, chr7:96644701-96644902, chr6:144608097-144608298, chr17:62775107-62775308, chr6:17281246-17281447, chr17:59539594-59539795, chr10:131498350-131498576, chr6:143999585-143999786, chr7:5458780-5458981, and chr2:177054059-177054426.
[0024] In some embodiments, the methylated biomarkers include chr19:13198677-13198878, chr6:25882281-25882482, chr6:25882382-25882583, chr2:232545785-232545986, chr10:94303998-94304199, chr1:50881885-50882086, chr9:130700842-130701043, chr9:96068585-96068786, chr6:28303851-28304336, and chr17:5953. 9353-59539707,chr9:135037068-135037269,chr7:96644701-96644902 , chr6:144608097-144608298, chr17:62775107-62775308, chr6:1728124 6-17281447,chr17:59539594-59539795,chr10:131498350-131498576, chr6:143999585-143999786, chr7:5458780-5458981, chr2:177054059-1 77054426,chr2:176994061-176994568,chr10:90966580-90966887,chr 1:43832835-43833036, chr12:51318406-51318607, chr20:31148589-31 148790,chr6:126949342-126949543,chr10:126429186-126429387,chr 1:48233421-48233622, chr2:237476488-237476689, chr2:19557080-195 57476, chr19:42927934-42928135, chr10:128594020-128594221, chr1: 18969596-18969797,chr1:225662379-225662580,chr20:44838900-4483 9101, chr19:12899476-12899677, chr4:74862011-74862212, chr1:9118 4332-91184533, chr7:19812427-19812628, chr2:177054492-177054693,Any at least one of the following: chr9:126769909-126770110, chr15:74725581-74725782, chr15:40340149-40340350, chr1:233749552-233749753, chr7:6866700-6866924, chr14:36983461-36983662, chr10:102905600-102905801, chr1:160712658-160712859, chr2:7017706-7017907, and chr16:30817087-30817288.
[0025] In some embodiments, the methylated biomarkers include chr19:13198677-13198878, chr6:25882281-25882482, chr6:25882382-25882583, chr2:232545785-232545986, chr10:94303998-94304199, chr1:50881885-50882086, chr9:130700842-130701043, chr9:96068585-96068786, chr6:28303851-28304336, and chr17:5953. 9353-59539707,chr9:135037068-135037269,chr7:96644701-96644902 , chr6:144608097-144608298, chr17:62775107-62775308, chr6:1728124 6-17281447,chr17:59539594-59539795,chr10:131498350-131498576, chr6:143999585-143999786, chr7:5458780-5458981, chr2:177054059-1 77054426,chr2:176994061-176994568,chr10:90966580-90966887,chr 1:43832835-43833036, chr12:51318406-51318607, chr20:31148589-31 148790,chr6:126949342-126949543,chr10:126429186-126429387,chr 1:48233421-48233622, chr2:237476488-237476689, chr2:19557080-195 57476, chr19:42927934-42928135, chr10:128594020-128594221, chr1: 18969596-18969797,chr1:225662379-225662580,chr20:44838900-4483 9101, chr19:12899476-12899677, chr4:74862011-74862212, chr1:9118 4332-91184533, chr7:19812427-19812628, chr2:177054492-177054693,chr9:126769909-126770110,chr15:74725581-74725782,chr15:40340149-40340350,chr1:233749552-233749753,chr7:6866700-6866924,chr14:36983461-36983662,chr10:102905600-102905801,chr1:160712658-160712859,chr2:7017706-7017907,chr16:30817087-30817288,chr6:10385045-10385246,chr2:63276397-63276598,chr6:28304370-28304571,chr17:8532678-8532879,chr1:18971975-18972176,chr3:15450877-15451078,chr1:51983638-51983839,chr12:54418011-54418212,chr14:61111437-61111638,chr11:62308432-62308633,chr10:131498289-131498490,chr6:28303954-28304241,chr15:65197802-65198043,chr2:191684930-191685131,chr14:23775665-23775866,chr10:131330618-131330819,chr19:12939466-12939667,chr2:19557394-19557595,chr1:200443203-200443404,chr2:175193256-175193457,chr10:131309043-131309244,chr2:176947984-176948185,chr1:180182537-180182738,chr2:175193389-175193598,chr16:86612986-86613187,chr1:226556812-226557013,chr22:47173565-47173766,chr7:92238283-92238484,chr19:51231655-51231856,chr7:92237965-92238236,chr4:154073359-154073560,chr20:23968749-23968950, chr1:197887568-197887769, chr3:128210029-128210260, chr8:106104599-106104800, chr10:71892512-7 1892713, chr10:88517527-88517728, chr7:43690166-43690367, chr16:89034057-89034258, chr19:58095347-58095548, chr3:9464355- 9464556, chr7:27232554-27232755, chr12:67613922-67614123, chr7:41869754-41869955, chr1:167868662-167868863, chr19:1466887-1467112, chr12:112035204-112035405, chr1:53528890-53529111, chr2:238578255-238578456, and chr14:36990953-36991154.
[0026] In some embodiments, the methylated biomarker also includes at least one of the other markers selected from Table 1.
[0027] In other embodiments of the present invention, the use of reagents for detecting the above-mentioned methylation biomarkers is disclosed in the preparation of kits for predicting, detecting, classifying, monitoring treatment, prognosticating or otherwise evaluating EGFR gene mutations in lung cancer somatic cells.
[0028] In other embodiments of the present invention, a lung cancer somatic cell EGFR gene mutation auxiliary detection kit is disclosed, comprising reagents for detecting the degree of methylation difference of the above-mentioned methylation biomarkers.
[0029] In some embodiments, the kit is prepared using polymerase chain reaction (PCR), in situ hybridization (ISH), enzyme mutation detection, chemical splicing mismatch, mass spectrometry, gene chip, or gene sequencing, or a combination thereof.
[0030] In some embodiments, the detection technologies employed in the above kits include, but are not limited to, RT-PCR, immunoPCR, nested PCR, fluorescent PCR, in situ PCR, membrane-bound PCR, anchored PCR, immobilized PCR, asymmetric PCR, long-distance PCR, parachute PCR, and gradient PCR; high-throughput detection technologies include, but are not limited to, simplified genome methylation sequencing, whole genome methylation sequencing, DNA enrichment sequencing, pyrophosphate sequencing, and sulfite conversion sequencing; mass spectrometry-based detection technologies such as GC-MS, LC-MS, MALDI-TOFMS, FT-MS, ICP-MS, and SIMS; and chip-based detection platforms such as 450K and 850K methylation detection technologies.
[0031] In some embodiments, the detection methods used in the above kits include, but are not limited to, at least one of the following: quantitative real-time PCR, methylation-specific PCR, digital PCR, DNA methylation chip, targeted DNA methylation sequencing, whole-genome methylation sequencing, and DNA methylation mass spectrometry.
[0032] In other embodiments of the present invention, the application of the above-described kit in predicting, detecting, classifying, monitoring treatment, assessing prognosis, or otherwise evaluating EGFR gene mutations in lung cancer somatic cells is disclosed.
[0033] In other embodiments of the present invention, a method for assisting in the detection of EGFR gene mutations in lung cancer somatic cells is disclosed. This method includes the following steps: extracting peripheral blood DNA from a biological sample to be tested; converting the DNA to bisulfite; and detecting the degree of methylation difference of the aforementioned methylation biomarkers.
[0034] In some embodiments, the above methods include, but are not limited to, the following technologies: methylation-specific PCR, sulfite PCR sequencing, real-time quantitative methylation-specific PCR, etc.; high-throughput detection technologies include simplified genome methylation sequencing, whole genome methylation sequencing, DNA enrichment sequencing, pyrophosphate sequencing, sulfite conversion sequencing, etc.; detection technologies based on mass spectrometry and other detection platforms; and chip-based detection platforms, such as 450K and 850K methylation detection technologies.
[0035] The present invention will be described in detail below with reference to the accompanying drawings and specific embodiments.
[0036] The detailed information on the methylated biomarkers (methylated regions) involved in this invention is shown in Table 1 below.
[0037] Table 1
[0038]
[0039]
[0040]
[0041]
[0042]
[0043]
[0044]
[0045]
[0046] Wherein intronic refers to an intron, intergenic to an intergenic sequence, exonic to an exon, upstream to an upstream segment, and downstream to a downstream segment.
[0047] Example 1
[0048] This embodiment discloses a detection method for 224 methylation regions in this invention to assist in the detection of EGFR gene mutations in lung cancer somatic cells, specifically including the following steps:
[0049] I. Sample Information
[0050] The 20 lung cancer samples included 7 women and 13 men, aged between 21 and 78 years, with a mean age of 56.9 years. The primary diagnoses were adenocarcinoma in 10 cases, squamous cell carcinoma in 1 case, and other types in 9 cases. Pathological staging included 1 case of stage I, 4 cases of stage III, 14 cases of stage IV, and 1 case with missing staging record (a brief description of different cancer stages is as follows: Stage I: Tumor in situ, not yet spread to any lymph nodes, potentially completely resectable surgically; Stage II: Tumor smaller than 5 cm but spread to nearby lymph nodes, or between 5 cm and 7 cm and potentially spread to any nearby lymph nodes, or larger than 7 cm and not yet spread to nearby lymph nodes but potentially invade the lung tissue). Near tissue structure; Stage III cancer: all tumor states more severe than stage II, which may spread to extrapulmonary lymph nodes or invade nearby tissues within the lung, but have not yet metastasized to distant sites, making complete surgical removal of the tumor difficult; Stage IV cancer: the tumor has metastasized to distant sites (to the contralateral lung, pleura, pericardium, or spread to distant parts of the body via the bloodstream); all 20 peripheral blood samples underwent whole-exome and RNA-seq sequencing and variant analysis, obtaining information such as SNVs and Indels. The samples were grouped according to EGFR mutant and EGFR wild-type samples, resulting in 14 EGFR_mut and 6 EGFR_wt samples.
[0051] II. Database Construction Process and Methods
[0052] 1. Peripheral blood DNA extraction and methylation library construction
[0053] 1.1 Extraction of DNA from peripheral blood.
[0054] The DNA extraction steps for the peripheral blood samples from lung cancer were performed according to the instructions of QIAGEN's DNeasy Blood & Tissue Kit.
[0055] 1.2 Transformation
[0056] The extracted peripheral blood DNA (50 ng) was subjected to bisulfite conversion, which deaminated unmethylated cytosine in the DNA to uracil, while the methylated cytosine remained unchanged, resulting in bisulfite-converted DNA. The conversion was performed according to the instructions of Zymo Research's EZ DNA Methylation-Lightning Kit.
[0057] 1.3 End-of-pipe repair
[0058] The 17 μL sample after the above transformation was added to the following reagents for reaction:
[0059]
[0060] Place the sample in a PCR instrument and perform the reaction according to the following procedure:
[0061]
[0062] When the second step of the PCR reaction (95℃) reaches 5 minutes, immediately remove the sample from the PCR instrument and place it directly in ice for at least 2 minutes before proceeding to the next step.
[0063] 1.4 Connection I
[0064] Prepare the following reaction solution:
[0065] Components Single dosage (μl) The product of the previous reaction 20 <![CDATA[H2O]]> 4 MLB1 buffer 8 MLR1 reagent 2 MLR5 reagent 2 MLE1 enzyme 2 MLE5 enzyme 2 Reaction Mixed Volume 40
[0066] Place the sample in a PCR instrument and perform the reaction according to the following procedure:
[0067] 37℃ 30min 95℃ 5min 10℃ hold Hot cap 105℃
[0068] 1.5 Amplification I
[0069] Prepare the following reaction solution
[0070]
[0071]
[0072] Place the sample in a PCR instrument and perform the reaction according to the following procedure:
[0073]
[0074] 1.6 Purification I:
[0075] To purify the product after amplification reaction I, add 166 μL of AgencourtAMPure Beads diluted 1:6 (equilibrate at room temperature for half an hour beforehand), and elute with 21 μL of EB. The specific purification steps are as follows:
[0076] Centrifuge the product from the previous step. Add 166 μl of 1:6 diluted Agencourt AMPure Beads to each sample and mix thoroughly by pipetting. Incubate at room temperature for 5 min. Centrifuge again and incubate on a magnetic rack for 5 min. Aspirate the supernatant. Add 200 μl of 80% EtOH, incubate for 30 s, aspirate the ethanol, repeat once, centrifuge, place the PCR tube on a magnetic rack, aspirate the remaining ethanol, and open the cap to dry the magnetic beads for 2–3 min, being careful not to over-dry. Add 21 μl of EB for elution, mix thoroughly by pipetting, and incubate at room temperature for 3 min. Centrifuge again and incubate on a magnetic rack for 3 min. Transfer 20 μl of supernatant to a new PCR tube.
[0077] 1.7 Connection II
[0078] Prepare the following reaction solution:
[0079] Components Volume (μl) Previous reaction volume 20 <![CDATA[H2O]]> 4 MSB1 buffer 8 MSR1 reagent 2 MSR5 reagent 2 MSE1 enzyme 2 MSE5 enzyme 2 Total volume 40
[0080] Place the sample in a PCR instrument and perform the reaction according to the following procedure.
[0081] temperature time Cycle number 37℃ 30min 1 95℃ 5min 1 10℃ Hold 1
[0082] 1.8 Indexing PCR (Construction of Amplified Product Library)
[0083] Prepare the following reaction solution:
[0084] Components Volume (μl) Previous reaction volume 40 <![CDATA[H2O]]> 6 2XKAPAHiFiHotStartReadyMix 8 I5 connector primers 2 I7 connector primers 2 Total volume 100
[0085] Place the sample in a PCR instrument and perform the reaction according to the following procedure.
[0086]
[0087] 1.9 Purification II
[0088] The product from the indexing PCR reaction was purified by adding Agencourt AM Pure Beads (which need to be equilibrated at room temperature for half an hour beforehand), and eluted with 41 μl of EB. The specific purification steps are as follows:
[0089] Centrifuge the product from the previous step. Add 71 μl of undiluted Agencourt AM PureBeads to each sample and mix thoroughly by pipetting. Incubate at room temperature for 5 min. Centrifuge and incubate on a magnetic rack for 5 min. Aspirate the supernatant. Add 200 μl of 80% EtOH, incubate for 30 s, aspirate the ethanol, repeat the step once, centrifuge, place the PCR tube on a magnetic rack, and aspirate the remaining ethanol. Open the cap and dry the magnetic beads for 2–3 min, being careful not to over-dry them. Add 41 μl of EB for elution, mix thoroughly by pipetting, and incubate at room temperature for 3 min. Centrifuge and incubate the PCR tube on a magnetic rack for 3 min. Transfer 20 μl of supernatant to a new PCR tube. Qubit quantification: Quantify the library using 1 μl of the Qubit dsDNA HS Assay Kit.
[0090] 2. Oligonucleotide probe capture enrichment was performed on the pre-constructed samples to obtain a final library for specific regions. The hybridization capture kit was IDT's xGen Lockdown Reagents; the instructions were followed precisely.
[0091] 3. The hybridized captured samples were sequenced using an Illumina sequencer to obtain the sequencing results.
[0092] 4. Analysis of offline data:
[0093] The raw data from the sequencer were processed using routine bioinformatics analysis. First, low-quality reads (low QC, short length, too many N, etc.) were filtered using FASTP. Then, adapters, common sequences, and PolyA / T were removed from both ends of the reads to obtain the ideal insert sequence (target region). After comparing these reads with the corresponding positions of HG19 using BISMark, the reads were deduplicated according to UMI to obtain the real read data (bamfile) captured by the probe for each sample. The bamfile was statistically analyzed to obtain methylation data for subsequent data reanalysis.
[0094] 5. The raw sequencing data were cleaned and processed [Liang, W., et al., Non-invasive diagnosis of early-stage lung cancer using high-throughput targeted DNA methylation sequencing of circulating tumor DNA (ctDNA). 2019.9(7):p.2056.] and the percentage of methylated cytosine in each region (β value) was determined based on the reads.
[0095] 6. Methylation detection information for these 6 EGFR_wt and 14 EGFR_mut samples (the 14 samples contained 2 nonframeshift deletions, 2 nonframeshift deletion-insertions, and 13 nonsynonymous SNVs; some samples had multiple mutation types) was analyzed using the 224 markers in Table 1. The heatmap is shown below. Figure 1 The 20 samples were randomly divided 50 times in a 1:1 ratio (balancing the number of wt and mut samples in each division). In each division, a Random Forest model was built on the training set. This model was then used on the test set to calculate the risk score for each sample. The risk score was compared with the standard diagnostic criteria to obtain the discrimination sensitivity, specificity, AUC, NPV, and PPV of the methylation region combination. The AUC graph after 50 models is shown below. Figure 2 As shown in Table 2, the average probability of each marker was calculated for 50 modeling iterations. The top 5 markers were selected, and their predictive performance AUCs were shown in Table 2 below. The AUCs show that these markers have good predictive performance (the ranking derived from the importance of model features differs slightly from the ranking of the predictive performance AUCs of each marker, but the overall trend of the two rankings is consistent. The AUC levels of the following top 5 markers all belong to the first tier).
[0096] Table 2 shows the prediction performance (AUC) of the top 5 markers across 20 samples.
[0097] marker ID AUC chr19:13198677-13198878 0.9191 chr6:25882281-25882482 0.9200 chr6:25882382-25882583 0.9038 chr2:232545785-232545986 0.9163 chr10:94303998-94304199 0.9210
[0098] Example 2
[0099] For the 14 EGFR_mut samples in Example 1 (these 14 samples contained 2 nonframeshift deletions, 2 nonframeshift deletion-insertions, and 13 nonsynonymous SNVs; some samples had multiple mutation forms), they were used as the positive group, along with 6 EGFR_wt samples as the negative group. Using the same 50-segmentation method as in Example 1, and with combinations of 5, 10, 20, 50, and 100 markers respectively, a Random Forest model was developed, where the 5-marker was...
[0100] chr19:13198677-13198878, chr6:25882281-25882482, chr6:25882382-25882583,
[0101] chr2:232545785-232545986, chr10:94303998-94304199; combinations of 10 markers, 20 markers, 50 markers, and 100 markers are random additions to a base of 5 markers. For example, a 10-marker combination might be chr19:13198677-13198878, chr6:25882281-25882482, chr6:25882382-25882583, chr2:232545785-232 545986, chr10:94303998-94304199, chr1:50881885-50882086, chr9:130700842-130701043, chr9:96068585-96068786, chr6 :28303851-28304336, chr17:59539353-59539707), 20marker (chr19:13198677-13198878, chr6:25882281-25882482, chr6:25 882382-25882583, chr2:232545785-232545986, chr10:94303998-94304199, chr1:50881885-50882086, chr9:130700842-130 701043, chr9:96068585-96068786, chr6:28303851-28304336, chr17:59539353-59539707, chr9:135037068-135037269, chr7 :96644701-96644902, chr6:144608097-144608298, chr17:62775107-62775308, chr6:17281246-17281447, chr17:59539594- 59539795, chr10:131498350-131498576, chr6:143999585-143999786, chr7:5458780-5458981, chr2:177054059-177054426), 50marker(chr19:13198677-13198878,chr6:25882281-25882482,chr6:25882382-25882583,chr2:232545785-232545986,chr10:94303998-94304199,chr1:50881885-50882086,chr9:130700842-130701043,chr9:96068585-96068786,chr6:28303851-28304336,chr17:59539353-59539707,chr9:135037068-135037269,chr7:96644701-96644902,chr6:144608097-144608298,chr17:62775107-62775308,chr6:17281246-17281447,chr17:59539594-59539795,chr10:131498350-131498576,chr6:143999585-143999786,chr7:5458780-5458981,chr2:177054059-177054426,chr2:176994061-176994568,chr10:90966580-90966887,chr1:43832835-43833036,chr12:51318406-51318607,chr20:31148589-31148790,chr6:126949342-126949543,chr10:126429186-126429387,chr1:48233421-48233622,chr2:237476488-237476689,chr2:19557080-19557476,chr19:42927934-42928135,chr10:128594020-128594221,chr1:18969596-18969797,chr1:225662379-225662580,chr20:44838900-44839101,chr19:12899476-12899677,chr4:74862011-74862212,
[0102] chr1:91184332-91184533,chr7:19812427-19812628,chr2:177054492-177054693,
[0103] chr9:126769909-126770110,chr15:74725581-74725782,chr15:40340149-40340350,
[0104] chr1:233749552-233749753,chr7:6866700-6866924,chr14:36983461-36983662,
[0105] chr10:102905600-102905801,chr1:160712658-160712859,chr2:7017706-7017907,
[0106] chr16:30817087-30817288)、 100marker (chr19:13198677-13198878,chr6:25882281-25882482,
[0107] chr6:25882382-25882583,chr2:232545785-232545986,chr10:94303998-94304199,
[0108] chr1:50881885-50882086,chr9:130700842-130701043,chr9:96068585-96068786,
[0109] chr6:28303851-28304336,chr17:59539353-59539707,chr9:135037068-135037269,
[0110] chr7:96644701-96644902,chr6:144608097-144608298,chr17:62775107-62775308,
[0111] chr6:17281246-17281447,chr17:59539594-59539795,chr10:131498350-131498576,
[0112] chr6:143999585-143999786,chr7:5458780-5458981,chr2:177054059-177054426,
[0113] chr2:176994061-176994568,chr10:90966580-90966887,chr1:43832835-43833036,
[0114] chr12:51318406-51318607,chr20:31148589-31148790,chr6:126949342-126949543,
[0115] chr10:126429186-126429387,chr1:48233421-48233622,chr2:237476488-237476689,
[0116] chr2:19557080-19557476,chr19:42927934-42928135,chr10:128594020-128594221,
[0117] chr1:18969596-18969797,chr1:225662379-225662580,chr20:44838900-44839101,
[0118] chr19:12899476-12899677,chr4:74862011-74862212,chr1:91184332-91184533,
[0119] chr7:19812427-19812628,chr2:177054492-177054693,chr9:126769909-126770110,
[0120] chr15:74725581-74725782,chr15:40340149-40340350,chr1:233749552-233749753,
[0121] chr7:6866700-6866924,chr14:36983461-36983662,chr10:102905600-102905801,
[0122] chr1:160712658-160712859,chr2:7017706-7017907,chr16:30817087-30817288,
[0123] chr6:10385045-10385246,chr2:63276397-63276598,chr6:28304370-28304571,
[0124] chr17:8532678-8532879,chr1:18971975-18972176,chr3:15450877-15451078,
[0125] chr1:51983638-51983839,chr12:54418011-54418212,chr14:61111437-61111638,
[0126] chr11:62308432-62308633,chr10:131498289-131498490,chr6:28303954-28304241,
[0127] chr15:65197802-65198043,chr2:191684930-191685131,chr14:23775665-23775866,
[0128] chr10:131330618-131330819,chr19:12939466-12939667,chr2:19557394-19557595,
[0129] chr1:200443203-200443404,chr2:175193256-175193457,chr10:131309043-131309244,
[0130] chr2:176947984-176948185,chr1:180182537-180182738,chr2:175193389-175193598,
[0131] chr16:86612986-86613187,chr1:226556812-226557013,chr22:47173565-47173766,
[0132] chr7:92238283-92238484, chr19:51231655-51231856, chr7:92237965-92238236, chr4:154073359- 154073560, chr20:23968749-23968950, chr1:197887568-197887769, chr3:128210029-128210260, c hr8:106104599-106104800, chr10:71892512-71892713, chr10:88517527-88517728, chr7:43690166 -43690367,chr16:89034057-89034258,chr19:58095347-58095548,chr3:9464355-9464556,chr7:27 232554-27232755, chr12:67613922-67614123, chr7:41869754-41869955, chr1:167868662-1678688 63, chr19:1466887-1467112, chr12:112035204-112035405, chr1:53528890-53529111, chr2:2385782 (55-238578456, chr14:36990953-36991154). The mean AUC, sensitivity, and specificity of the modeling under these marker numbers are shown in Table 3. Under 5, 10, 20, 50, and 100 markers, the number of samples classified as EGFR_mut was 12, 13, 13, 13, and 12, respectively. This indicates that different combinations of these methylated regions can serve as markers to assist in the detection of EGFR gene mutations in somatic cell samples.
[0133] Table 3
[0134]
[0135] Where auc is the area under the ROC curve, se is the sensitivity, sp is the specificity, acc is the accuracy, ppv is the positive predictive value, npv is the negative predictive value, adjppv is the corrected positive predictive value, and adjnpv is the corrected negative predictive value, and so on.
[0136] Example 3
[0137] For the 14 EGFR_mut samples (positive group) and 6 EGFR_wt samples (negative group) from Example 1 (a total of 20 samples), these samples were randomly labeled according to a 14 positive: 6 negative ratio. First, the samples were randomly segmented 50 times, similar to Example 1. Then, following Example 2, combinations of 5, 10, 20, 50, and 100 markers were used to model the data using a Random Forest. This process was independently repeated 25 times. The mean AUC, sensitivity, and specificity of the modeling were statistically analyzed for the above marker numbers, as shown in Table 4 below.
[0138] Table 4
[0139]
[0140] The results showed that, as a random reference, Example 3, the model had no ability to distinguish between randomly labeled sample groups (Mean auc < 0.5).
[0141] The above results indicate that grouping and modeling according to the factual situation of the samples (as shown in Examples 1 and 2) results in a model that performs much better than the randomized reference (as shown in Example 3), demonstrating that the findings in Examples 1 and 2 have practical biological significance.
[0142] The technical features of the above embodiments can be combined in any way. For the sake of brevity, not all possible combinations of the technical features in the above embodiments are described. However, as long as there is no contradiction in the combination of these technical features, they should be considered to be within the scope of this specification.
[0143] The embodiments described above are merely illustrative of several implementations of the present invention, and while the descriptions are relatively specific and detailed, they should not be construed as limiting the scope of the invention patent. It should be noted that those skilled in the art can make various modifications and improvements without departing from the concept of the present invention, and these all fall within the protection scope of the present invention. Therefore, the protection scope of this invention patent should be determined by the appended claims.
Claims
1. The application of a reagent for detecting a combination of methylated biomarkers in the preparation of a kit for predicting or detecting EGFR gene mutations in somatic lung cancer cells, characterized in that, The methylation biomarker combination includes chr19:13198677-13198878, chr6:25882281-25882482, chr6:25882382-25882583, chr2:232545785-232545986 and chr10:94303998-94304199, and the methylation regions of the methylation biomarkers are aligned to the corresponding positions of hg19.
2. The application according to claim 1, characterized in that, The methylation biomarker combination also includes chr1:50881885-50882086, chr9:130700842-130701043, chr9:96068585-96068786, chr6:28303851-28304336 and chr17:59539353-59539707, and the methylation regions of the methylation biomarkers are aligned to the corresponding positions of hg19.
3. The application according to claim 1, characterized in that, The methylated biomarker combination also includes chr1:50881885-50882086, chr9:130700842-130701043, chr9:96068585-96068786, chr6:28303851-28304336, chr17:59539353-59539707, chr9:135037068-135037269, chr7:96644701-96644902, and chr6:144608097-14460 8298, chr17:62775107-62775308, chr6:17281246-17281447, chr17:59539594-59539795, chr10:131498350-131498576, chr6:143999585-143999786, chr7:5458780-5458981 and chr2:177054059-177054426, the methylated regions of the methylated biomarkers are aligned to the corresponding positions of hg19.
4. The application according to claim 1, characterized in that, The methylated biomarker combination also includes chr1:50881885-50882086, chr9:130700842-130701043, chr9:96068585-96068786, chr6:28303851-28304336, chr17:59539353-59539707, chr9:135037068-135037269, chr7:96644701-96644902, chr6:144608097-144608298, chr17:62775107-62775308, chr6:17281246-17281 447, chr17:59539594-59539795, chr10:131498350-131498576, chr6:143 999585-143999786, chr7:5458780-5458981, chr2:177054059-177054426, chr2:176994061-176994568, chr10:90966580-90966887, chr1:43832835 -43833036,chr12:51318406-51318607,chr20:31148589-31148790,chr6: 126949342-126949543,chr10:126429186-126429387,chr1:48233421-48 233622, chr2:237476488-237476689, chr2:19557080-19557476, chr19:42 927934-42928135,chr10:128594020-128594221,chr1:18969596-189697 97, chr1:225662379-225662580, chr20:44838900-44839101, chr19:12899 476-12899677,chr4:74862011-74862212,chr1:91184332-91184533,chr 7:19812427-19812628, chr2:177054492-177054693, chr9:126769909-126 770110,chr15:74725581-74725782,chr15:40340149-40340350,chr1:23 3749552-233749753, chr7:6866700-6866924, chr14:36983461-36983662,chr10:102905600-102905801, chr1:160712658-160712859, chr2:7017706-7017907 and chr16:30817087-30817288, the methylated regions of the methylated biomarkers are aligned to the corresponding positions of hg19.
5. The application according to claim 1, characterized in that, The methylated biomarker combination also includes chr1:50881885-50882086, chr9:130700842-130701043, chr9:96068585-96068786, chr6:28303851-28304336, chr17:59539353-59539707, chr9:135037068-135037269, chr7:96644701-96644902, chr6:144608097-144608298, chr17:62775107-62775308, chr6:17281246-17281 447, chr17:59539594-59539795, chr10:131498350-131498576, chr6:143 999585-143999786, chr7:5458780-5458981, chr2:177054059-177054426, chr2:176994061-176994568, chr10:90966580-90966887, chr1:43832835 -43833036,chr12:51318406-51318607,chr20:31148589-31148790,chr6: 126949342-126949543,chr10:126429186-126429387,chr1:48233421-48 233622, chr2:237476488-237476689, chr2:19557080-19557476, chr19:42 927934-42928135,chr10:128594020-128594221,chr1:18969596-189697 97, chr1:225662379-225662580, chr20:44838900-44839101, chr19:12899 476-12899677,chr4:74862011-74862212,chr1:91184332-91184533,chr 7:19812427-19812628, chr2:177054492-177054693, chr9:126769909-126 770110,chr15:74725581-74725782,chr15:40340149-40340350,chr1:23 3749552-233749753, chr7:6866700-6866924, chr14:36983461-36983662,chr10:102905600-102905801,chr1:160712658-160712859,chr2:7017706-7017907,chr16:30817087-30817288,chr6:10385045-10385246,chr2:63276397-63276598,chr6:28304370-28304571,chr17:8532678-8532879,chr1:18971975-18972176,chr3:15450877-15451078,chr1:51983638-51983839,chr12:54418011-54418212,chr14:61111437-61111638,chr11:62308432-62308633,chr10:131498289-131498490,chr6:28303954-28304241,chr15:65197802-65198043,chr2:191684930-191685131,chr14:23775665-23775866,chr10:131330618-131330819,chr19:12939466-12939667,chr2:19557394-19557595,chr1:200443203-200443404,chr2:175193256-175193457,chr10:131309043-131309244,chr2:176947984-176948185,chr1:180182537-180182738,chr2:175193389-175193598,chr16:86612986-86613187,chr1:226556812-226557013,chr22:47173565-47173766,chr7:92238283-92238484,chr19:51231655-51231856,chr7:92237965-92238236,chr4:154073359-154073560,chr20:23968749-23968950,chr1:197887568-197887769,chr3:128210029-128210260,chr8:106104599-106104800,chr10:71892512-71892713,chr10:88517527-88517728,chr7:43690166-43690367, chr16:89034057-89034258, chr19:58095347-58095548, chr3:9464355- 9464556, chr7:27232554-27232755, chr12:67613922-67614123, chr7:41869754-41869955, chr1:1 The methylated regions of the methylated biomarkers 67868662-167868863, chr19:1466887-1467112, chr12:112035204-112035405, chr1:53528890-53529111, chr2:238578255-238578456 and chr14:36990953-36991154 are aligned to the corresponding positions of hg19.
Citation Information
Patent Citations
Method for synchronously detecting gene mutation and methylation and application thereof
CN108456721A
Kit and method for detecting methylation of EGFR gene
CN111304305A
